Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1994 Sep 17;309(6956):711–715. doi: 10.1136/bmj.309.6956.711

The therapeutic use of bisphosphonates.

J E Compston 1
PMCID: PMC2540833  PMID: 7950525

Full text

PDF
711

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S., Baroni M. C., Broggini M., Carratelli L., Caruso I., Gnessi L., Laurenzi M., Lombardi A., Norbiato G., Ortolani S. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporos Int. 1993;3 (Suppl 3):S21–S27. doi: 10.1007/BF01623004. [DOI] [PubMed] [Google Scholar]
  2. Boonekamp P. M., van der Wee-Pals L. J., van Wijk-van Lennep M. M., Thesing C. W., Bijvoet O. L. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986 Feb;1(1):27–39. [PubMed] [Google Scholar]
  3. Boyce B. F., Smith L., Fogelman I., Johnston E., Ralston S., Boyle I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1984 Apr 14;1(8381):821–824. doi: 10.1016/s0140-6736(84)92272-4. [DOI] [PubMed] [Google Scholar]
  4. Compston J. E. HRT and osteoporosis. Br Med Bull. 1992 Apr;48(2):309–344. doi: 10.1093/oxfordjournals.bmb.a072549. [DOI] [PubMed] [Google Scholar]
  5. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs. 1991 Dec;42(6):919–944. doi: 10.2165/00003495-199142060-00003. [DOI] [PubMed] [Google Scholar]
  6. Fleisch H. New bisphosphonates in osteoporosis. Osteoporos Int. 1993;3 (Suppl 2):S15–S22. doi: 10.1007/BF01623222. [DOI] [PubMed] [Google Scholar]
  7. Frost H. M. The ADFR concept revisited. Calcif Tissue Int. 1984 Jul;36(4):349–353. doi: 10.1007/BF02405344. [DOI] [PubMed] [Google Scholar]
  8. Gallacher S. J., Fenner J. A., Anderson K., Bryden F. M., Banham S. W., Logue F. C., Cowan R. A., Boyle I. T. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax. 1992 Nov;47(11):932–936. doi: 10.1136/thx.47.11.932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harris S. T., Watts N. B., Jackson R. D., Genant H. K., Wasnich R. D., Ross P., Miller P. D., Licata A. A., Chesnut C. H., 3rd Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993 Dec;95(6):557–567. doi: 10.1016/0002-9343(93)90350-x. [DOI] [PubMed] [Google Scholar]
  10. Mulder H., Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 1994 Apr;33(4):348–350. doi: 10.1093/rheumatology/33.4.348. [DOI] [PubMed] [Google Scholar]
  11. Ott S. M. Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res. 1993 Dec;8 (Suppl 2):S597–S606. doi: 10.1002/jbmr.5650081329. [DOI] [PubMed] [Google Scholar]
  12. Papapoulos S. E., Landman J. O., Bijvoet O. L., Löwik C. W., Valkema R., Pauwels E. K., Vermeij P. The use of bisphosphonates in the treatment of osteoporosis. Bone. 1992;13 (Suppl 1):S41–S49. doi: 10.1016/s8756-3282(09)80009-4. [DOI] [PubMed] [Google Scholar]
  13. Patel S., Lyons A. R., Hosking D. J. Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use. Drugs. 1993 Oct;46(4):594–617. doi: 10.2165/00003495-199346040-00003. [DOI] [PubMed] [Google Scholar]
  14. Reginster J. Y., Lecart M. P., Deroisy R., Sarlet N., Denis D., Ethgen D., Collette J., Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23;2(8678-8679):1469–1471. doi: 10.1016/s0140-6736(89)92927-9. [DOI] [PubMed] [Google Scholar]
  15. Reid I. R., Heap S. W., King A. R., Ibbertson H. K. Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet. 1988 Nov 12;2(8620):1144–1144. doi: 10.1016/s0140-6736(88)90566-1. [DOI] [PubMed] [Google Scholar]
  16. Reid I. R., King A. R., Alexander C. J., Ibbertson H. K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet. 1988 Jan 23;1(8578):143–146. doi: 10.1016/s0140-6736(88)92721-3. [DOI] [PubMed] [Google Scholar]
  17. Storm T., Steiniche T., Thamsborg G., Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 1993 Feb;8(2):199–208. doi: 10.1002/jbmr.5650080211. [DOI] [PubMed] [Google Scholar]
  18. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  19. Valkema R., Vismans F. J., Papapoulos S. E., Pauwels E. K., Bijvoet O. L. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner. 1989 Jan;5(2):183–192. doi: 10.1016/0169-6009(89)90095-0. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES